- $7.68m
- -$11.32m
- $0.08m
Aclarion up as software shows benefit in assisting back pain surgeries
Brief: Aclarion Announces Publication Of 2YR Outcomes In Clinical Trial
Brief: Aclarion Inc - On March 3, Received Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard From Nasdaq
Brief: Aclarion Inc - On December 20, Co Received A Written Notice From Nasdaq For Failing To Comply With The Minimum Bid Price Requirement
NASDAQ RESUMED AT 10:53 AM
NASDAQ RESUMED AT 10:53 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:59 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:59 AM
NASDAQ TRADE HALT REASON NOT AVAILABLE AT 04:00 AM